

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>In re</i> Patent Application of)	
)	
Imran AHMAD <i>et al.</i>)	Group Art Unit: Unassigned
)	
Continuation of Application No.: 09/540,050)	Examiner: Unassigned
)	
Filed: August 26, 2003)	Confirmation No.: Unassigned
)	
For: D AND L ETHERLIPID)	
STEREoisomers and LIPOSOMES)	

FIRST
INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the attached information in conformance with 37 C.F.R. §§ 1.97 and 1.98. In accordance with 37 C.F.R. § 1.98, a copy of each of the listed documents, except those documents which were previously made of record in prior application No. 09/540,050, filed March 31, 2000, is enclosed.

Since the documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b) no fee or statement is required.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: _____

Teresa Stanek Rea
Registration No. 30,427

P.O. Box 1404
Alexandria, VA 22313-1404
(703) 836-6620
Date: August 26, 2003

Substitute for forms 1449A/PTO & 1449B/PTO	ATTORNEY'S DKT NO. 033388-566	CONTINUATION OF APPLICATION No. 09/540,050
	APPLICANT Imran AHMAD et al	
	FILING DATE August 26, 2003	GROUP Unassigned

**FIRST INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

U.S. PATENT DOCUMENTS				
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	3,752,886		Munder <i>et al.</i>	08-14-1973
	4,159,988		Eibl <i>et al.</i>	07-03-1979
	4,163,748		Eibl <i>et al.</i>	08-07-1979
	4,382,035		Eibl	05-03-1983
	4,734,225		Eibl	03-29-1988
	4,804,789		Eibl	02-14-1989
	4,920,016		Allen <i>et al.</i>	04-24-1990
	4,965,391		Counsell <i>et al.</i>	10-23-1990
	4,983,397		Schroit <i>et al.</i>	01-08-1991
	5,013,556		Woodle <i>et al.</i>	05-07-1991
	5,436,234	A	Eibl	//07-25-1995
	5,762,958		Mayhew <i>et al.</i>	06-09-1998
	5,932,242		Franklin <i>et al.</i>	08-03-1999
	5,942,246	A	Mayhew <i>et al.</i>	08-24-1999
	5,965,159		Mayhew <i>et al.</i>	10-12-1999
	6,007,839		Mayhew <i>et al.</i>	12-28-1999
	6,017,557		Franklin <i>et al.</i>	01-25-2000
	6,180,137	B1	Mayhew <i>et al.</i>	01-30-2001

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation Yes No
	61-22022	A	Japan	01-30-1986	
	072294		Japan	07--1986	
	1,583,661		Great Britain	01-28-1981	
	0,213,523	B1	Europe	12-12-1990	
	4,132,345		DE	04-01-1993	
	4,408,011		DE	11-02-1995	
	93/04673		WIPO	03-18-1993	
	93/08202		WIPO	04-29-1993	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for forms 1449A/PTO & 1449B/PTO	ATTORNEY'S DKT NO. 033388-566	CONTINUATION OF APPLICATION NO. 09/540,050
	APPLICANT Imran AHMAD et al	
	FILING DATE August 26, 2003	GROUP Unassigned

**FIRST INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

FOREIGN PATENT DOCUMENTS					
	94/27580		WIPO	12-08-1994	

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Baker <i>et al.</i> , "Inhibition of Chronic Relapsing Experimental Allergic Encephalomyelitis in the Mouse by the Alkyl-Lysophospholipid ET-18-OCH ₃ ," <u>Int. J. Immuno Pharm</u> , 13(4):395 (1991).
	Bazill <i>et al.</i> , "Role of Endocytosis in the Action of Ether Lipids on WEHI-3B, HL60, and FEDCP-Mix A4 Cells," <u>Cancer Res.</u> 50:7505 (1990).
	Berdel, "Membrane-interactive lipids as experimental anticancer drugs," <u>Br. J. Cancer</u> 64:208 (1991).
	Berdel, "Ether Lipids and Derivatives as Investigational Anticancer Drugs," <u>Onkologie</u> 13:245 (1990).
	Bhatia <i>et al.</i> , "Stereospecific Synthesis of Antitumor Active Thioether PAF Analogs," <u>Lipids</u> 26(12):1424 (1991).
	Blume <i>et al.</i> , "Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times," <u>Biochim. Biophys. Acta.</u> , 1149:180-184 (1993).
	Daicho <i>et al.</i> , "Effects of alkyl glycosides incorporated into liposomes prepared from synthetic amphiphiles on their tissue distribution in Ehrlich solid tumor-bearing mice," <u>BBA</u> , 1107:61 (1992).
	Darnell <i>et al.</i> , <u>Molecular Cell Biology</u> , pp. 573-575 (1986), Scientific American Books, Inc., New York.
	Deamer and Uster, "Liposome Preparation: Methods and Mechanisms," <u>Liposomes</u> , pp. 27-52 (1983), M. Ostro, ed., Marcel Dekker, Inc., New York.
	Dietzfelbinger <i>et al.</i> , "Removal of Breast Cancer Cells from Bone Marrow by In Vitro Purging with Ether Lipids and Cryopreservation," <u>Cancer Reserach</u> , 53:3747 (1993).
	Dive <i>et al.</i> , "Multiparametric Flow Cytometry of the Modulation of Tumor Cell Membrane Permeability by Developmental Antitumor Ether Lipid SRI 62-834 in EMT6 Mouse Mammary Tumor and HL-60 Human Promyelocytic Leukemia Cells," <u>Cancer Research</u> , 51:799 (1991).
	Gabizon <i>et al.</i> , "Prolongation of Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs," <u>Pharm. Research</u> , 10(5):703 (1993).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for forms 1449A/PTO & 1449B/PTO	ATTORNEY'S DKT NO. 033388-566	CONTINUATION OF APPLICATION NO. 09/540,050
	APPLICANT Imran AHMAD et al	
	FILING DATE August 26, 2003	GROUP Unassigned

**FIRST INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Kaufmann-Kolle <i>et al.</i> , " <i>Liposomal Hexadecylphosphocholine (HEPC): In Vitro and In Vivo Application</i> ," <u>Chemical Abstracts</u> , (4), 10.08.
	Kucera <i>et al.</i> , " <i>Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation</i> ," <u>AIDS Research & Human Retroviruses</u> , 6(4):491 (1990).
	Layton <i>et al.</i> , " <i>The Interaction of Liposomes with Cells: The Relation of Cell Specific Toxicity to Lipid Composition</i> ," <u>Eur. J. Cancer</u> , 16:64 (1980).
	Lewis <i>et al.</i> , " <i>The Mesomorphic Phase Behavior of Lipid Bilayers</i> ," <u>The Structure of Biological Membranes</u> , pp. 73-155 at pp. 123-126 (1992), P. Yeagle, ed., CRC Press, Inc., Boca Raton, Fl.
	Mende <i>et al.</i> , " <i>Effect of ET-18-OCH₃/Cholesterol Liposomes on the Membrane Potential of Isolated Endothelial Cells</i> ," <u>Pharmazie</u> , 44(2) (1989)
	Muschiol <i>et al.</i> , " <i>Alkyl Phosphocholine: Toxicity and Anticancer Properties</i> ," <u>Lipids</u> , 22(11):930 (1987).
	Nairn, <u>Reington's Pharmaceutical Science</u> , pp. 1492-1517 (1985), A. Gennaro, ed., Mack Publishing Co., Easton, PA.
	Park <i>et al.</i> , " <i>Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo</i> ," <u>Biochim. Biophys. Acta.</u> , 1108:257 (1992).
	Powis <i>et al.</i> , " <i>Selective Inhibition of Phosphatidylinositol Phospholipase C by Cytotoxic Ether Lipid Analogues</i> ," <u>Cancer Research</u> , 52:2835 (1992)
	Powis <i>et al.</i> , " <i>The Cell Membrane and Cell Signals as Targets in Cancer Chemotherapy</i> ," <u>Cancer Research</u> , 50:2203 (1990).
	Reed <i>et al.</i> , " <i>Antineoplastic Ether-linked Phospholipid induces differentiation of acute myelogenous leukemic KG-1 cells into macrophage-like cells</i> ," <u>Life Sci.</u> , 49:1221 (1991).
	Runge <i>et al.</i> , " <i>Destruction of Human Solid Tumors by Alkyl Lysophospholipids</i> ," <u>JNCL</u> , 64(6):1301 (1980).
	Tritton <i>et al.</i> , " <i>How to Kill Cancer Cells: Membranes and Cell Signaling as Targets in Cancer Chemotherapy</i> ," <u>Cancer Cells</u> , 2(4):95 (1990).
	Workman, " <i>Antitumor Ether Lipids: Endocytosis as a Determinant of Cellular Sensitivity</i> ," <u>Cancer Cells</u> , 3(8):315 (1991).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for forms 1449A/PTO & 1449B/PTO FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTORNEY'S DKT NO. 033388-566	CONTINUATION OF APPLICATION NO. 09/540,050
	APPLICANT Imran AHMAD et al	
	FILING DATE August 26, 2003	GROUP Unassigned

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Workman <i>et al.</i> , "Plastelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-O-Methyl and SRIU 62-834 in HL-60 promyelocytic leukaemia cells," <u>Biochem. Pharmacol.</u> , 41(2):319 (1991).
	Zeisig <i>et al.</i> , "Antineoplastic activity in vitro of free and liposomal alkylphosphocholines," <u>Anti-Cancer Drugs</u> , 4:57 (1993).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.